Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00907387
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
72
Enrollment
INDUSTRY
Sponsor class
Conditions
Lateral Canthal Lines
Interventions
DRUG:
RT001
DRUG:
RT001
OTHER:
Placebo
Sponsor
Revance Therapeutics, Inc.